Surgical Management of Female Urinary Incontinence in the Elderly

Dr. Ashley Cox, MD, FRCSC, MSc Residency Program Director Department of Urology



Objectives

 To gain an understanding of what common surgical options exist for treating different types of female urinary incontinence


 To gain an understanding of the basic indications and contraindications of surgical procedures for female urinary incontinence

To begin to apply these concepts in a case-based approach



Female Urinary Incontinence

- Stress
- Urgency
- Mixed
- Overflow






Investigations

- History
- Physical exam
- Urine studies
- Voiding diary
- Assessment of bother/ QOL impairment
- Uroflow/scan
- +/- cystoscopy under local anesthetic
- +/- Urodynamics
- +/- renal bladder US







Decision-Making



- Different types of incontinence require different surgical procedures
- Conservative and medical therapies must be maximized
- Shared care approach
- Individualized approach



Decision-Making





Goal: Maximize quality of life, minimize harm!



Surgical Options: Overview

| Type of Incontinence | Pathophysiology | Surgical Option |
|---------------------------------------|---|--|
| Stress Urinary Incontinence (SUI) | Weakness of pelvic floor supports and urinary sphincter (urethral hypermobility, intrinsic sphincter deficiency) | Mid-urethral mesh sling Pubovaginal sling with autologous fascia Urethral bulking agent Retropubic suspension (Burch procedure) |
| Urgency Urinary Incontinence (UUI) | Detrusor overactivity | Injection of onabotulinumtoxinA Sacral neuromodulation |
| Mixed Urinary Incontinence (MUI) | Combination of above | Combination of above depending on what is predominant |
| Overflow Urinary Incontinence | Obstruction (rare in female) Hypocontractile bladder | Relief obstruction Surgery not an option for treatment of hypocontractile bladder (rare exception with SNM) |



Stress Urinary Incontinence

- Involuntary leakage of urinary with increased intraabdominal pressure (i.e. exertion, coughing, laughing)
- 51% of woman seeking care for SUI are over 70, but only 16% undergo surgical treatment (Abrams P, Neurourol Urodyn 2002)
- Elderly woman often excluded from clinical trials on incontinence surgeries



Stress Urinary Incontinence

Surgery is effective

Table 2. Cure/dry rates of different anti-incontinence procedures for SUI

| Category | Procedure | Objective cure rate (short term) | Objective cure rate (long term) | Level of evidence |
|----------------------|------------------|----------------------------------|---------------------------------|-------------------|
| | AFS | 90% | 82% after 48 mo ⁵⁹ | Α |
| BNS | CFS | 74% | 80% up to 43 mo ⁵⁹ | В |
| | Porcine dermis | 73% | 54% at 36 mo ^{54,61} | В |
| MUS | Retropubic (TVT) | 88% | 90% at 10 y ⁶² | Α |
| | TOT | 84% | 84% at 5 y ⁶² | В |
| Open colposuspension | Burch | | | |
| | MMK | 85-90% | 70% at 5 y ⁶³ | Α |

: Can Urol Assoc J 2012;6(5):354-63.



Case 1.

- 75 yo married, independent, female
- 3 ppd due to SUI. No previous incontinence procedures. G4P4
- Med Hx: HTN Meds: Ramipril, vagifem All: none
- Surg hx: 1 c/s
- Plays tennis; is sexually active
- O/E: BMI 28, benign abdomen, urethral hypermobility, ++ SUI, minimal cystocele, tissue well estrogenized
- All required investigations show uncomplicated SUI
- Options for surgical management?



Midurethral Mesh Slings

- Developed in 1996 (Ulmsten U, Int Urogyne J, 1996)
- Most commonly performed surgery for female SUI, most well studied (Ford A, Cochrane Review, 2015)



- AKA: Tension-free vaginal tape (TVT), transobturator tape (TOT), mesh tape, TVT-obturator approach (TVT-o)
- As effective, if not more effective, than more invasive approaches such as pubovaginal sling and open retropubic procedures (Fusco F, Eur Urol 2017)
- Outpatient procedure for most; general or spinal anesthetic
- Negative media attention has led to slight decrease in use of MUS and to patient concerns



Midurethral Mesh Slings

Retropubic Approach





Figure 73-8. Midurethral sling as placed by the suprapubic approach (any technique).



Midurethral Mesh Slings





Retropubic vs Transobturator Approach

- Retropubic approach slightly more effective (Richter H, NEJM, 2010)
 - 81% vs 77% objective success rate at 12 mos
- Difference in side effect profile

 Transobturator optimal choice: obese, multiple prior abdominal surgeries, surgeon skillset

Midurethral Mesh Sling

- Contraindications: AGE NOT A CONTRAINDICATION!!
 - Inability to tolerate surgery
 - Active infection
 - Coagulopathy
 - Previous mesh complications pain, erosion
 - Urethral fistula
 - Urethral diverticulectomy
 - Can't access the vagina
 - Relative prior radiation
 - Patient preference



• 'But at my age Doctor, will the surgery work'?



- 'But at my age Doctor, will the surgery work'?
 - Age may be risk factor for sling failure in the long-term (>5 yr follow-up) (Laterza R, PLoS One, 2018)



A Multicenter, Prospective, Randomized Clinical Trial Comparing Tension-Free Vaginal Tape Surgery and No Treatment for the Management of Stress Urinary Incontinence in Elderly Women

L. Campeau, ¹ L.M. Tu, ² M.C. Lemieux, ¹ A. Naud, ³ G. Karsenty, ¹ E. Schick, ⁴ and J. Corcos ^{1*}

Department of Urology, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Canada

²Department of Urology, Université de Sherbrooke, Sherbrooke, Montreal, Canada

³Department of Urology, Université Laval, Quebec, Montreal, Canada

⁴Division of Urology, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, Canada

TABLE III. Results at 6 Months Follow-Up

| | TVT | Control | Mean difference (Control-TVT, 95%CI) | <i>P</i> -value |
|----------------------|---------------------------------|----------------------------------|--------------------------------------|-----------------|
| Raw scores | | | | |
| I-QOL | 96.5 ± 15.5 | 61.6 ± 19.8 | -34.9 (-44.2, -25.6) | < 0.0001 |
| Patient Satisfaction | 8.0 ± 2.7 | 2.0 ± 2.4 | -6.0 (-7.4, -4.7) | < 0.0001 |
| Urinary Problems | $\textbf{4.5} \pm \textbf{4.3}$ | 11.6 ± 3.5 | 7.2 (5.1, 9.2) | < 0.0001 |
| Change in scores | | | • • • | |
| I-QOL | 38.7 ± 224 | $\textbf{2.7} \pm \textbf{16.4}$ | -36.0 (-46.4, -25.5) | <0.0001 |
| Patient Satisfaction | 5.5 ± 3.5 | -1.0 ± 3.4 | -6.4 (-8.2, -4.6) | < 0.0001 |
| Urinary Problems | -6.6 ± 3.9 | -0.8 ± 2.9 | 5.8 (3.9, 7.7) | < 0.0001 |

Neurourology and Urodynamics 26:990-994 (2007)



Midurethral Sling Procedures for Stress Urinary Incontinence in Women Over 80 Years

Kobi Stav,* Peter L. Dwyer, Anna Rosamilia, Lore Schierlitz, Yik N. Lim and, Joseph Lee Department of Urogynaecology (affiliated to Melbourne University), Mercy Hospital for Women, Melbourne, Victoria, Australia

Neurourology and Urodynamics 29:1262–1266 (2010)

TABLE I. Demographic, Surgical, and Preoperative Characteristics of Sling Patients — Comparison Between Elderly and Younger Patients (n = 1112)

| | Age \geq 80 years (n = 96) | Age $<$ 80 years (n $=$ 1016) | <i>P</i> -value |
|-----------------------------|------------------------------|-------------------------------|-----------------|
| Mean age—years ^a | 85 ± 3.5 (85) [80-95] | $58 \pm 11 \ (58) \ [20-74]$ | < 0.001 |
| Mean BMI ^a | $27.2 \pm 4.9 (26) [18-42]$ | $27.5 \pm 4.7 (27) [17-46]$ | 0.49 |

- Subjective cure rate 81% (80+) vs. 85% (<80), p<0.32
- > 80 (n=96)
 - no difference between retropubic and transobturator approach
 - Higher rate of admission/ LOS
 - More likely to have urinary retention postop (37% vs. 9%, p<0.001)



Case 2.

- 75 yo married, independent, female
- 3 ppd due to SUI.
- Med Hx: HTN Meds: Ramipril, vagifem All: none
- Sound familiar??



Case 2.

- 75 yo married, independent, female
- 3 ppd due to SUI.
- Med Hx: HTN Meds: Ramipril, vagifem All: none
- Sound familiar?? Same as case 1 EXCEPT...

• Surg hx: 1 c/s, AND *previous midurethral sling (TVT)* for stress incontinence 3 yrs earlier that worked for 12 months. She is not keen on a second mesh procedure.

Options for surgical management?




Pubovaginal Sling with Autologous Fascia


- Older technique being done more frequently due to negative media attention surrounding potential mesh complications (Ghoniem, G Int Urogyne J 2018)
- More invasive surgical technique
- Use fascia instead of synthetic mesh to create a sling for increased support under the urethra
- General or spinal anesthetic, 1.5 hour operation, in hospital 1-2 days, lithotomy position
- Equivalent objective and subjective success rates to the MUS
- Data specific to elderly patients is lacking



Pubovaginal Sling with Autologous

Fascia





Pubovaginal Sling with Autologous Fascia

- Indications:
 - failed previous therapies
 - urethral mesh complications
 - concomitant urethral reconstruction/ urethral diverticulectomy
 - patient who is adverse to the use of mesh
- Outcomes
 - Lacking data in the elderly population
 - In general, similar to TVT (~80-85% success rate at 5 yrs)
 - Higher risk of retention, voiding dysfunction post-operatively



Case 3


- 92 yo active female with MUI
- ++ bothered by 3 ppd for SUI and complains of mild UUI
- Med hx: MI, HTN, DM, arthritis
- Meds: metoprolol, altace, furosemide, metformin, Vit D, Calcium,
 ASA, amoung others
- Surg hx: appendectomy, hysterectomy, cholecystectomy
- Lives with her son
- O/E: Thin, ambulatory, vaginal exam ++ atrophy, + SUI with minimal mobility, mild cystocele
- Investigations show SUI, good emptying
- Any reasonable surgical option?



Urethral Bulking Agent



Fig. 1 The Urethroscope, connected to the rotatable sheath, with inflow/outflow tubings. The needle (23G x 12 cm) is placed in the working-canal connected to a 1 ml syringe with Bulkamid



Urethral Bulking Agent

- Bulkamid® (polyacrylamide hydrogel -2.5% cross-linked polyacrylamide and 97.5% water)
- Outcomes inferior to more invasive surgical approaches
 - 12 mos: 47.2% no SUI episodes; 77% considered themselves improved or cured (Sokol E, 2014)
- RCTs include elderly females
 - Lose G, Int Urogyne J 2010 median age 56 (range 29-82)
 - Sokol E, J Urol 2014 median age 58 (range 23-93)
- Remains a reasonable option for elderly patients who would not tolerate more invasive surgery or have poor vaginal access/ atrophy



Urgency Urinary Incontinence




Urgency Urinary Incontinence

 'The sudden loss of urine accompanied by or immediately proceeded by the urgency to void' (ICS)

- ~2.5-4% of general population and increases with age (Irwin D, Eur Urol 2006)
- Larger impact on QOL than SUI

Slings are NOT indicated to treat UUI in the absence of SUI




Case 4. Refractory UUI

- 82 yo female with UUI wearing 5 ppd, wet every night –can't make it to washroom on time, dx10, nx2
- ++ bothered
- 4 medications and conservative therapies failed
- Can't afford pads any longer
- Med hx: HTN, DM, COPD, hypothyroid
- Meds: metoprolol, Ramipril, Synthroid, metformin, Januvia, puffers, amoung others
- Surg hx: appendectomy, hysterectomy, c/s x 2
- Surgical options?



Refractory UUI



Third line therapies for OAB and UUI (CUA Guidelines, 2017)



Refractory UUI

Sacral Neuromodulation (InterstimII, Medtronic)





Third line therapies for OAB and UUI (CUA Guidelines, 2017)



OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women A Randomized Clinical Trial

Cindy L. Amundsen, MD; Holly E. Richter, PhD, MD; Shawn A. Menefee, MD; Yuko M. Komesu, MD; Lily A. Arya, MD, MS; W. Thomas Gregory, MD; Deborah L. Myers, MD; Halina M. Zyczynski, MD; Sandip Vasavada, MD; Tracy L. Nolen, DrPH; Dennis Wallace, PhD; Susan F. Meikle, MD, MSPH; for the Pelvic Floor Disorders Network

- N=364
- Age: botox mean (SD) 62.9(11.5) vs 63.1(11.8)
- Botox reduced number of UUI episodes by -3.9 vs -3.3 episodes per day in the SNM group, p=0.01
- Botox led to higher rate of CIC and UTIs



OnabotulinumtoxinA (Botox)

Woman 65+ less likely than woman
 <65 to have symptom resolution (Komescu
 Y, Am J Obstet Gynecol, 2019)

 Older patients may be at higher risk of post-op urinary retention (Miotla P, Int Urogyne J 2017) and urinary tract infections (Komescu Y, Am J Obstet Gynecol, 2019)

| Residual volumes (ml) | Age (years), mean ± SD |
|---|---------------------------|
| Group 1 | 61.1 ± 14.5 |
| <50 ml | |
| (n = 106) Group 2 51–100 ml | 57.0 ± 12.1 |
| (n = 41) Group 3 | 60.7 ± 11.8 |
| 101–200 ml | |
| (n = 35) Group 4 | 68.5 ± 10.2^{a} |
| 201–350 ml | |
| (n = 13) Group 5 | 68.8 ± 11.2 ^b |
| urine retention requiring CISC $(n = 13)$ | |

OnabotulinumtoxinA (Botox)

OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects

Hann-Chorng Kuo¹

Drugs Aging (2016) 33:1-9



Table 1 Advantages and disadvantages of onabotulinumtoxinA intravesical injection treatment for overactive bladder in elderly patients, in comparison with oral medication


| comparison with oral medication | | | | |
|----------------------------------|---|--|--|--|
| | Advantages | Disadvantages | | |
| Bladder sensation | Decreases in frequency, nocturia and urgency episodes [51-54] | Decrease in bladder sensation, difficulty in urination [62] | | |
| Detrusor | Decrease in urgency urinary incontinence episodes [51-54] | Decrease in voiding pressure | | |
| contractility | | Decrease in voiding efficiency | | |
| | | Acute urinary retention [62] | | |
| Bladder capacity | Increase in voided volume, increase in cystometric bladder capacity [51-54] | Increase in post-void residual volume [64, 69] | | |
| | | Urinary retention [70] | | |
| Adverse events | Lack of systemic adverse events due to antimuscarinics or β ₃ -adrenoceptor agonism, such as dry mouth, constipation, blurred vision, dizziness, tachycardia, hypertension [51–54] | Local adverse events such as haematuria, pain during urination [70] | | |
| | | Increase in urinary tract infection incidence [52] | | |
| | | Clean intermittent catheterization may be necessary [55] | | |
| Central nervous system effect | No cognitive impairment in Parkinson's disease patients with overactive bladder [57, 58] | | | |
| Administration | Treatment 1-2 times per year [51-54] | Need for an injection | | |
| Long-term efficacy | Efficacy persists for >6 months [51–54, 70] | Efficacy is less persistent in the elderly than in general OAB patients [56] | | |



Drugs Aging (2016) 33:1-9

Sacral Neuromodulation

- Elderly patients (Angioli R, Int Urogyne J, 2013)
 - Mean age 76 (65-86)
 - At 1 yr: 27.8% improved, 55% UUI resolved, UUI episodes decreased from 6.3/d to 0.5/d; improved nocturia
 - No major post-operative complications





In Summary

 Different surgical approaches exist depending on the type of urinary incontinence

 For SUI, MUS synthetic slings and pubovaginal slings with fascia are options for elderly patients ABLE and WILLING to tolerate surgery

 For SUI, urethral bulking agents are available for patients who are unable (or unwilling) to undergo more invasive procedures -less effective however



In Summary

- For UUI, both onabotulinumtoxinA and sacral neuromodulation are options for patients who have symptoms refractory to medications
- Botox can be performed under local anesthetic or sedation while SNM requires a general anesthetic
- Advanced age is associated with higher risk of complications from Botox
- Age is NOT an absolute contraindication to surgery for female urinary incontinence

- Thank you
- Questions?



